Melanoma patients benefit from the expression of CEACAM1-3S as a consequence of enhanced expression of the NKG2D ligands MICA, ULBP2 and DNAM-1 ligand CD155 on the surface of melanoma cells, thus presenting these cells as targets for NK cell mediated cytolysis [72]. This evidence concerns the gene CD226 and melanoma.